PGNY vs UNH: How Progyny and UnitedHealth Group Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: PGNY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. PGNY and UNH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined PGNY and UNH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Progyny sells a carve-out fertility benefit to self-insured employers. Rather than a dollar cap or a cycle cap, clients buy bundles that Progyny calls Smart Cycles, delivered through a credentialed network of fertility clinics, with an in-house team of care advocates guiding members through treatment. Progyny Rx, the attached specialty pharmacy solution, handles the medications and accounts for roughly a third of revenue. The company launched with five clients in 2016 and had ~604 fertility and family building clients as of June 30, 2026, covering ~7.2 million lives at employers ranging from ~1,000 to ~300,000 employees. It has since extended the same benefits-management model into pregnancy and postpartum, menopause and midlife, leave navigation and parent and child wellbeing, all sold into the same HR buyer.

Full PGNY guide

UnitedHealth Group is the largest US health insurer and one of the largest healthcare companies in the world. It runs through two main engines. UnitedHealthcare is the insurance arm, providing employer, individual, Medicare Advantage, and Medicaid health plans to tens of millions of members. Optum is the faster-growing health-services arm: Optum Health (physician groups and care delivery, including value-based care), Optum Insight (healthcare data, analytics, and technology), and Optum Rx (one of the largest pharmacy benefit managers in the country). The combination lets UnitedHealth manage both the financing and the delivery of care, capturing margin across the system and using vast claims data to manage costs. Headquartered in Minnetonka, Minnesota, UnitedHealth is a Dow component and one of the largest companies in the S&P 500 by revenue. Its scale, vertical integration, and Medicare Advantage leadership define its competitive position.

Full UNH guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• PGNY drivers: Client wins and covered lives; Utilization, the variable that decides the year.
• UNH drivers: Optum growth engine; Medicare Advantage scale.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Client concentration is the structural risk: contracts run three years but carry termination options after year one on 30 to 90 days' notice, and the departure of one large client removed ~$48.5 million of 2025 revenue and suppressed reported growth through the first half of 2026. For UNH, unitedHealth faces a difficult medical-cost environment: rising utilization (especially in Medicare Advantage) can spike the medical loss ratio and compress margins, as the company has experienced.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick PGNY if you believe its drivers more; UNH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the PGNY and UNH guides.

PGNY. At ~$28 the shares carry roughly 21x to 22x guided GAAP earnings and roughly 13x to 14x guided adjusted earnings, which back out the ~$40 million of first-half stock compensation. Because Progyny passes clinic and pharmacy costs through, price-to-sales of ~1.7x understates the real multiple; enterprise value against ~$322 million of trailing gross profit lands near 6x, and against guided adjusted EBITDA near 8x. Those are levels that price single-digit growth and a repeat of the 2024 client loss rather than a return to the twenty-percent growth of 2021 through 2023.

UNH. UnitedHealth's revenue is enormous but its insurance margins are thin by design, so earnings hinge on the medical loss ratio and Optum's higher-margin growth. The valuation reflects scale and integration but has been pressured by cost inflation, regulatory uncertainty, and reputational headwinds. The market weighs Optum's durable growth against insurance-cycle and political risk.

Headline figures (approximate, August 2026): PGNY shows revenue (ttm) ~$1.31 billion, with FY2025 at ~$1.289 billion and FY2024 at ~$1.167 billion, clients and covered lives ~604 fertility and family building clients as of June 30, 2026 (~542 a year earlier), ~7.2 million covered lives, utilization ~0.56% of all members in Q2 2026 versus ~0.55%, and ~0.85% for the first half versus ~0.82%, profitability (ttm) ~$79 million GAAP net income and ~$225 million adjusted EBITDA (~17.5% margin), on ~$201 million of operating cash flow; UNH shows revenue (ttm) ~$400 billion, operating margin ~6-8%, net income (ttm) ~$15-22 billion (sensitive to medical costs), medical loss ratio ~85-89%.

PGNY and UNH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined PGNY and UNH exposure against your real portfolio. It is not an investment adviser.